Loading...
OTCM
HKMPF
Market cap4.57bUSD
Oct 19, Last price  
22.14
Name

Hikma Pharmaceuticals PLC

Chart & performance

D1W1MN
OTCM:HKMPF chart
P/E
—
P/S
—
EPS
1.98
Vol. 1Y
—
Shs. 5Y
-1.32%
Rev. 5Y
7.42%
Div Yld LY
—
Div Yld TTM
—
Revenues
3.35b
+7.10%
317,022,000448,796,000580,656,000636,884,000730,936,000918,025,0001,109,000,0001,365,000,0001,489,000,0001,440,000,0001,950,000,0001,936,000,0002,070,000,0002,207,000,0002,341,000,0002,553,000,0002,517,000,0002,875,000,0003,127,000,0003,349,000,000
Net income
410m
+14.33%
54,522,00062,576,00057,125,00077,683,00098,849,00080,107,000100,000,000212,000,000278,000,000252,000,000155,000,000-843,000,000282,000,000486,000,000431,000,000421,000,000188,000,000190,000,000359,000,000410,434,081
CFO
367m
-35.01%
29,992,00043,117,00057,872,000105,518,000138,786,000102,639,000182,161,000337,000,000425,000,000366,000,000293,000,000443,000,000430,000,000472,000,000464,000,000638,000,000530,000,000608,000,000564,000,000366,531,928
Dividend
Aug 14, 20260.38 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hikma Pharmaceuticals PLC is a global pharmaceutical company that specializes in the development, production, commercialization, and distribution of a wide array of generic, branded, and in-licensed medicines. These pharmaceuticals are provided in various final dosage forms, including solid, semi-solid, liquid, and injectable formats. The company's business activities are organized into three core divisions: Injectables, Generics, and Branded products. The Injectables division primarily supplies generic injectable medications for hospital use. Its Generics segment focuses on offering oral and other non-injectable generic formulations to the retail market. The Branded segment, conversely, delivers branded generic drugs and products licensed from third parties to both retail consumers and hospitals. Hikma's product portfolio addresses numerous therapeutic areas, such as anti-infectives, cardiovascular health, central nervous system conditions, diabetes, oncology, pain management, and respiratory illnesses. The company maintains a substantial international footprint, operating throughout the United Kingdom, the United States, the Middle East, North Africa, Europe, and other global markets. Founded in 1978, Hikma Pharmaceuticals PLC has its headquarters in London, UK.

Related entities

Subsidiaries
HIKMA VENTURES LIMITED

Key people

Khalid Nabilsi
Chief Financial Officer · since 2011
Hafrun Fridriksdottir
President - Generics · since 2024
Bill Larkins
President - Injectables · since 2023
Chief People Officer · since 2023
Susan Ringdal
Executive Vice President - Strategic Planning and Global Affairs · since 2020
Executive Vice President - Corporate Development and M and A · since 2018
Julie Hill
Senior Vice President - Corporate Quality Compliance and Health and Safety · since 2024
Executive Chairman of the Board, Interim Chief Executive Officer · since 2025
Riad Mishlawi
Chief Executive Officer, Executive Director · since 2023
Helen Middlemist
Company Secretary · since 2024
Ali Al-Husry
Non-Executive Director · since 2005
Laura Balan
Non-Executive Independent Director - Workforce Engagement · since 2025
Non-Executive Independent Director · since 2019
Non-Executive Independent Director · since 2025
Senior Non-Executive Independent Director · since 2023
Non-Executive Independent Director · since 2020
Deneen Vojta
Non-Executive Independent Director · since 2022
IPO date
Nov 01, 2005
Employees
8,700
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
1 New Burlington Place
London, LND W1S 2HR
GB
Previous name
HIKMA PHARMACEUTICALS PLC
Previous name
HIKMA PHARMA PUBLIC LIMITED COMPANY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT